Abstract：
Significant research advances in our understanding of psoriatic disease have led to the development of several highly selective, effective, and safe topical and systemic treatments. These treatments have led to unprecedented levels of disease clearance and control for most patients with psoriasis with cutaneous disease. However, there remains a need for improved treatments for those patients with recalcitrant disease, psoriatic arthritis, or nonplaque disease variants. Recently approved therapies and investigational products in ongoing clinical development programs that target IL-17A/F, IL-23, TYK2, PDE4, AhR or IL-36 cytokine signaling are improving the clinician\'s ability to care for a broader range of patients affected by psoriasis.
摘要：
我们对牛皮癣疾病的理解的重大研究进展导致了几种高度选择性的发展，有效,和安全的局部和全身治疗。对于大多数患有皮肤疾病的牛皮癣患者来说，这些治疗方法导致了前所未有的疾病清除和控制水平。然而,对于那些患有顽固性疾病的患者，仍然需要改进的治疗方法，银屑病关节炎,或非斑块疾病变体。最近批准的治疗和研究产品在正在进行的临床开发计划，针对IL-17A/F，IL-23，TYK2，PDE4，AhR或IL-36细胞因子信号正在改善临床医生对更广泛的牛皮癣患者的护理能力。
